|
시장보고서
상품코드
1764897
유럽의 녹내장 치료제 시장 : 예측 - 지역별 분석(약제 클래스별, 적응증별, 판매 채널별)(-2031년)Europe Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel |
||||||
유럽의 녹내장 치료제 시장은 2023년에 15억 2,983만 달러로 평가되었고, 2031년에는 19억 3,078만 달러에 이를 것으로 예측되며, 2023년부터 2031년까지의 CAGR은 3.0%를 나타낼 전망입니다.
제품 출시, 제휴, 인수 증가가 유럽 녹내장 치료제 시장을 활성화
녹내장 치료제 제조업체는 시장에서의 존재감을 보여주기 위해 전략적 제휴, 지리적 확대, 파트너십, 합병 및 인수, 제품 및 서비스 출시 등의 전략을 실시했습니다.
2024년 3월, 혁신적인 안구 약물 전달 기술을 전문으로 하는 MediPrint Ophthalmics는 2b상 녹내장 SIGHT-2 시험의 성공적인 종료를 발표했습니다.
2023년 12월 미국 식품의약국(FDA)은 고안압증(OHT) 또는 개방각 녹내장(OAG) 환자의 안압 하강을 적응증으로 하는 프로스타글란딘 아날로그 제형 iDose TR(트라보프로스트 방광내 임플란트) 75mcg의 신약 승인 신청(NDA)을 그라우코스사에 승인했습니다.
2022년 11월, 알콘은 Aerie Pharmaceuticals, Inc.를 인수했습니다. 이 인수에 의해 알콘은 로크라탄(네탈스질·라타노프로스트 점안액) 0.02%/0.005%, 로프레사(네탈스질 점안액) 0.02%, 안구건조증 치료제 제3상 후보의 AR-15512, 복수의 전임상·임상 안과용 의약품 후보의 파이프라인 Rocklatan과 Rhopressa는 개방 구석 각 녹내장 또는 고안압 환자의 안압 상승 억제를 적응증으로하는 Rho-kinase 억제제입니다. 이 인수로 알콘은 녹내장, 망막 및 안표면 질환 치료제를 포함한 포트폴리오를 확대하는 단계를 밟았습니다.
2022년 3월, 존슨 엔드 존슨 비전 케어는 케토티펜이라고 불리는 항히스타민제(렌즈 1장당 19㎍)를 배합한 콘택트렌즈, ACUVUE 세라비전의 새로운 변종의 FDA 승인을 취득했습니다. ACUVUE Theravision with Ketotifen은 알레르기성 안구 가려움증을 겪는 콘택트렌즈 사용자들에게 새로운 착용 경험을 제공하도록 고안된 최초의 제품입니다. 이러한 제품의 출시, 제휴, 인수는 녹내장 치료제 시장의 성장에 크게 기여하고 있습니다.
유럽의 녹내장 치료제 시장 개요
유럽의 녹내장 치료제 시장은 독일, 프랑스, 영국, 스페인, 이탈리아, 기타 유럽으로 구분됩니다. 녹내장 치료제 시장의 선수들에게 큰 성장 기회를 가져다 줄 것입니다. Sabel Vision Restoration Center(SAVIR)에 따르면, 이 나라에서는 약 50만명이 녹내장을 앓고 있습니다. 녹내장을 앓고 있는 사람의 10% 가까이가 궁극적으로 심각한 시력장애를 경험하지만, 완전한 실명에 이르는 사람은 거의 없습니다. 독일에서는 2021년 말까지 67세 이상의 노인이 1,620만명에 달하고, 2060년에는 2,160만명으로 증가할 것으로 예측되고 있습니다. 노화 인구의 급증으로 인한 녹내장의 현저한 유병률은 독일 전역에서 녹내장 치료제 수요를 촉진하고 있습니다.
유럽 녹내장 치료제 시장의 수익과 2031년까지의 예측(금액)
유럽 녹내장 치료제 시장의 세분화
유럽의 녹내장 치료제 시장은 약제 클래스별·적응증별·유통 채널별 및 국가별로 분류됩니다.
유럽의 녹내장 치료제 시장은 약물 등급별로 베타 차단제, 알파 아드레날린 작용제, 프로스타글란딘 유사체, 탄산 탈수 효소 억제제, 병용 약물 등으로 구분됩니다.
적응증의 관점에서 유럽 녹내장 치료제 시장은 개방 각도 녹내장, 폐쇄각 녹내장 등으로 분류됩니다.
유통 채널별로 유럽 녹내장 치료제 시장은 병원 약국, 소매 약국, 온라인 약국으로 분류됩니다.
국가별로 유럽 녹내장 치료제 시장은 독일, 프랑스, 이탈리아, 영국, 스페인, 기타 유럽으로 구분됩니다.
Alcon AG, AbbVie Inc, Bausch &Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, Santan Pharmaceutical Co., Ltd.는 유럽의 녹내장 치료제 시장입니다.
목차
제1장 서론
제2장 주요 요약
- 주요 인사이트
- 시장의 매력
제3장 분석 방법
- 2차 조사
- 1차 조사
- 가설의 책정
- 거시경제 요인분석
- 기초 수치의 개발
- 데이터의 삼각측량
- 국가 레벨 데이터
제4장 유럽의 녹내장 치료제 시장 : 주요 시장 역학
- 녹내장 치료제 시장 : 주요 시장 역학
- 시장 성장 촉진요인
- 녹내장 이환율 증가
- 제품 출시, 제휴, 인수 증가
- 시장 성장 억제요인
- 복약 컴플라이언스 문제
- 시장 기회
- 웨어러블 기술 개발
- 향후의 동향
- 새로운 약제 전달법의 개발
- 성장 촉진요인과 억제요인의 영향
제5장 녹내장 치료제 시장 : 유럽 시장의 분석
- 녹내장 치료제 시장의 수익(2021-2031년)
- 녹내장 치료제 시장 예측·분석
제6장 유럽의 녹내장 치료제 시장 분석 : 약제 클래스별
- β차단제
- α아드레날린 작용제
- 프로스타글란딘 유사체
- 탄산탈수효소 억제제
- 배합제
- 기타
제7장 유럽의 녹내장 치료제 시장 분석 : 적응증별
- 개방각 녹내장
- 폐쇄각 녹내장
- 기타
제8장 유럽 녹내장 치료제 시장 분석 : 유통 채널별
- 병원 약국
- 소매 약국
- 온라인 약국
제9장 유럽 녹내장 치료제 시장 분석 : 국가별 분석
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타 유럽
제10장 녹내장 치료제 시장 : 업계 정세
- 녹내장 치료제 시장에서의 성장 전략
- 유기적 성장 전략
- 무기적 성장 전략
제11장 기업 프로파일
- Alcon AG
- AbbVie Inc
- Bausch & Lomb Inc
- Viatris Inc
- Novartis AG
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
- Thea Pharma Inc
- Santen Pharmaceutical Co., Ltd.
제12장 부록
SHW 25.07.14The Europe glaucoma therapeutics market was valued at US$ 1,529.83 million in 2023 and is expected to reach US$ 1,930.78 million by 2031; it is estimated to register a CAGR of 3.0% from 2023 to 2031.
Increasing Number of Product Launches, Collaborations, and Acquisitions Fuels Europe Glaucoma Therapeutics Market
Glaucoma therapeutics manufacturers are implementing strategies such as strategic alliances, geographic expansions, partnerships, mergers & acquisitions, and product/service launches to mark their presence in the market.
In March 2024, MediPrint Ophthalmics, a company that specializes in innovative ocular drug delivery technologies, announced the successful completion of its Phase 2b Glaucoma SIGHT-2 study.
In December 2023, the US Food and Drug Administration (FDA) approved Glaukos Corporation's New Drug Application (NDA) for iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of IOP in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). The drug was approved for a single administration per eye.
In November 2022, Alcon acquired Aerie Pharmaceuticals, Inc. Through the transaction, Alcon acquired Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%; Rhopressa (netarsudil ophthalmic solution) 0.02%; AR-15512, a Phase 3 product candidate for dry eye disease; and a pipeline of several preclinical and clinical ophthalmic pharmaceutical product candidates. Rocklatan and Rhopressa are Rho-kinase inhibitors indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. With this acquisition, Alcon takes a step forward to broaden its portfolio with the inclusion of glaucoma, and retinal and ocular surface disease therapeutics.
In March 2022, Johnson & Johnson Vision Care, Inc. received FDA approval for its new ACUVUE Theravision variant, a type of contact lens containing an antihistamine called ketotifen (19 µg per lens). ACUVUE Theravision with Ketotifen is the first of its kind and is designed to provide a new wearing experience for contact lens users, experiencing allergic eye itch. Such product launches, collaborations, and acquisitions contribute significantly to the growth of the glaucoma therapeutics market.
Europe Glaucoma Therapeutics Market Overview
The Europe glaucoma therapeutics market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy contribute significant shares to the market in this region, and countries such as France, the UK, and Spain are likely to present significant growth opportunities for glaucoma therapeutics market players. The Europe glaucoma therapeutics market growth is ascribed to the rising number of glaucoma cases with the increasing aging population. Germany records a widespread occurrence of glaucoma. According to Sabel Vision Restoration Center (SAVIR), approximately half a million people are affected by glaucoma in this country. However, experts estimate that the actual number may be much higher due to unreported cases. Nearly 10% of all individuals suffering from glaucoma eventually experience serious vision impairments; nonetheless, almost none is likely to attain complete blindness. As per the Federal Statistical Office (Destatis), 16.2 million people in Germany were aged 67 and above by the end of 2021, and the number is projected to rise to 21.6 million by 2060. The probability of developing glaucoma and other eye diseases is likely to increase with aging. Thus, a significant prevalence of glaucoma due to the surging geriatric population propels the demand for glaucoma therapeutics across Germany.
Europe Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)
Europe Glaucoma Therapeutics Market Segmentation
The Europe glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.
Based on drug class, the Europe glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.
In terms of indication, the Europe glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.
By distribution channel, the Europe glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.
By country, the Europe glaucoma therapeutics market is segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Germany dominated the Europe glaucoma therapeutics market share in 2023.
Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Europe glaucoma therapeutics market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Key Insights
- 2.2 Market Attractiveness
3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Glaucoma Therapeutics Market - Key Market Dynamics
- 4.1 Glaucoma Therapeutics Market - Key Market Dynamics
- 4.2 Market Drivers
- 4.2.1 Mounting Incidence of Glaucoma Disease
- 4.2.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
- 4.3 Market Restraints
- 4.3.1 Medication Regimen Compliance Issues
- 4.4 Market Opportunities
- 4.4.1 Development of Wearable Technologies
- 4.5 Future Trends
- 4.5.1 Development of Novel Drug Delivery Methods
- 4.6 Impact of Drivers and Restraints:
5. Glaucoma Therapeutics Market - Europe Analysis
- 5.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
- 5.2 Glaucoma Therapeutics Market Forecast Analysis
6. Europe Glaucoma Therapeutics Market Analysis - by Drug Class
- 6.1 Beta Blockers
- 6.1.1 Overview
- 6.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 6.2 Alpha Adrenergic Agonists
- 6.2.1 Overview
- 6.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 6.3 Prostaglandins Analogues
- 6.3.1 Overview
- 6.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 6.4 Carbonic Anhydrase Inhibitors
- 6.4.1 Overview
- 6.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 6.5 Combination Drugs
- 6.5.1 Overview
- 6.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 6.6 Others
- 6.6.1 Overview
- 6.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7. Europe Glaucoma Therapeutics Market Analysis - by Indication
- 7.1 Open Angle Glaucoma
- 7.1.1 Overview
- 7.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 7.2 Angle Closure Glaucoma
- 7.2.1 Overview
- 7.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 7.3 Others
- 7.3.1 Overview
- 7.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8. Europe Glaucoma Therapeutics Market Analysis - by Distribution Channel
- 8.1 Hospital Pharmacy
- 8.1.1 Overview
- 8.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 8.2 Retail Pharmacy
- 8.2.1 Overview
- 8.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 8.3 Online Pharmacy
- 8.3.1 Overview
- 8.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
9. Europe Glaucoma Therapeutics Market - Country Analysis
- 9.1 Europe
- 9.1.1 Europe: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
- 9.1.1.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
- 9.1.1.2 Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 9.1.1.2.1 Germany: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 9.1.1.2.2 Germany: Glaucoma Therapeutics Market Breakdown, by Indication
- 9.1.1.2.3 Germany: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 9.1.1.3 France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 9.1.1.3.1 France: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 9.1.1.3.2 France: Glaucoma Therapeutics Market Breakdown, by Indication
- 9.1.1.3.3 France: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 9.1.1.4 United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 9.1.1.4.1 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 9.1.1.4.2 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Indication
- 9.1.1.4.3 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 9.1.1.5 Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 9.1.1.5.1 Italy: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 9.1.1.5.2 Italy: Glaucoma Therapeutics Market Breakdown, by Indication
- 9.1.1.5.3 Italy: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 9.1.1.6 Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 9.1.1.6.1 Spain: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 9.1.1.6.2 Spain: Glaucoma Therapeutics Market Breakdown, by Indication
- 9.1.1.6.3 Spain: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 9.1.1.7 Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
- 9.1.1.7.1 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 9.1.1.7.2 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Indication
- 9.1.1.7.3 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 9.1.1 Europe: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
10. Glaucoma Therapeutics Market - Industry Landscape
- 10.1 Growth Strategies in Glaucoma Therapeutics Market
- 10.2 Organic Growth Strategies
- 10.2.1 Overview
- 10.3 Inorganic Growth Strategies
- 10.3.1 Overview
11. Company Profiles
- 11.1 Alcon AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
- 11.2 AbbVie Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
- 11.3 Bausch & Lomb Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
- 11.4 Viatris Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
- 11.5 Novartis AG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
- 11.6 Sun Pharmaceutical Industries Ltd
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
- 11.7 Teva Pharmaceutical Industries Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
- 11.8 Thea Pharma Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
- 11.9 Santen Pharmaceutical Co., Ltd.
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
12. Appendix
- 12.1 About The Insight Partners
- 12.2 Glossary of Terms
